Drugmaker Cipla Limited on Sunday, 21 June announced the launch of experimental anti-viral drug remdesivir under its brand name Cipremi. Remdesivir is the only US FDA approved Emergency Use Authorisation (EUA) treatment for adult and pediatric patients hospitalized with suspected or laboratory-confirmed COVID-19 infection.
In May, US drugmaker Gilead Sciences extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla's generic version of remdesivir called Cipremi.